

Allergan plc  
Form 4  
August 09, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Basgoz Nesli

(Last) (First) (Middle)

CLONSHAUGH BUSINESS AND  
TECHNOLOGY  
PARK,, COOLOCK, CO.

(Street)

DUBLIN D17 E400

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol

Allergan plc [AGN]

3. Date of Earliest Transaction  
(Month/Day/Year)

08/05/2016

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares, par value \$0.0001	08/05/2016		M	1,889 A	\$ 97.62 6,672 <sup>(1)</sup>	D	
Ordinary Shares, par value \$0.0001	08/05/2016		S	758 D	\$ 253.02 5,914	D	
Ordinary Shares, par value	08/08/2016		A	201 A	\$ 248.31 6,115 <sup>(2)</sup> <sup>(3)</sup>	D	

\$0.0001

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 97.62	08/05/2016		M	1,889	<sup>(4)</sup> 08/07/2016	Ordinary Shares	1,889

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director 10% Owner Officer Other

Basgoz Nesli  
CLONSHAUGH BUSINESS AND TECHNOLOGY PARK,  
COOLOCK, CO.  
DUBLIN D17 E400

X

## Signatures

/s/ A. Robert D. Bailey, Attorney-in-Fact for the Reporting  
Person

08/09/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

## Edgar Filing: Allergan plc - Form 4

This option award was scheduled to expire pursuant to its terms on August 7, 2016, and was exercised on the last trading day prior to expiration.

- (2) These restricted stock units shall vest 100% on the earlier of (i) the day before the 2017 Annual Shareholder Meeting or (ii) May 4, 2017.
- (3) Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
- (4) This option became vested and exercisable in four equal installments commencing on August 7, 2006.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.